Skip to main content
Premium Trial:

Request an Annual Quote

Biomarker Developer LineaGen Closes $5.8M Series A Funding

NEW YORK (GenomeWeb News) – Salt Lake City-based startup LineaGen closed a $5.8 million round of series A funding, the company said Wednesday.
 
Investors included vSpring Capital, Sanderling Biomedical Ventures, and Mesa Verde Venture Partners.
 
The company plans to use the funds to launch its research program, which will rely on a strategic relationship with the University of Utah to discover and develop biomarkers for major disease areas, including autism, multiple sclerosis, osteoporosis, and chronic obstructive pulmonary disease.
 
Three scientific advisors to the firm are researchers at the University of Utah, and the company plans to use the school’s Utah Population Database, with records for over six million individuals, for its biomarker research.
 
The company also named Dinesh Patel of vSPring, Fred Middleton of Sanderling, and Dan Wood of Mesa Verde to its board of directors.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.